Semaglutide GLP-1 mimics the effects of GLP-1, which leads to decreased appetite, slower digestion, and increased feelings of fullness
Insulin secretion is enhanced only when blood glucose is elevated (glucose-dependent mechanism), substantially reducing hypoglycaemia risk compared to sulphonylureas
Studies indicate that 25 to 40 percent of weight lost on GLP-1 agonists can be lean mass, including muscle tissue
In two phase 3 clinical trials, retatrutide, a novel glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon triple-hormone receptor agonist, demonstrated significant weight loss and clinically meaningful improvements in health outcomes in people living with obesity and type 2 diabetes
Clin Ther 1999
It helps reduce dark spots and promotes a radiant complexion